Diagnosing mastocytosis requires a combination of clinical evaluation, blood tests, tissue biopsies, and genetic analysis. The specific workup depends on whether the disease is limited to the skin (cutaneous mastocytosis) or has spread to other organs (systemic mastocytosis). A formal diagnosis of systemic mastocytosis follows a structured set of criteria established by the World Health Organization, built around one major criterion and four minor criteria.
Where Diagnosis Typically Starts
Mastocytosis is often suspected after unexplained allergic-type reactions, anaphylaxis with no clear trigger, persistent skin lesions, or symptoms like chronic diarrhea, bone pain, and flushing. The first diagnostic step is usually a blood test measuring baseline serum tryptase, a protein released by mast cells. A level above 20 ng/mL is one of the minor criteria for systemic mastocytosis and a signal that further investigation is warranted.
Timing matters for tryptase testing. If you’ve recently had a severe allergic reaction, tryptase spikes temporarily. To count as a diagnostic criterion, the blood draw needs to happen well after all symptoms have resolved, so it reflects your true baseline rather than an acute spike. Other indirect clues that prompt deeper testing include unexplained osteoporosis, blood count abnormalities like elevated eosinophils, chronic gastrointestinal symptoms such as malabsorption or cramping, and recurrent episodes of anaphylaxis.
Diagnosing Skin Involvement
The most recognizable sign of cutaneous mastocytosis is red-brown macules, papules, or plaques on the skin. A key bedside test is Darier’s sign: the lesion is stroked five times with moderate pressure using a tongue depressor. Within several minutes, the stroked area develops visible redness and swelling that the surrounding normal skin does not. This distinguishes it from simple dermatographism, where stroking any area of skin causes a similar reaction.
When clinical appearance and Darier’s sign leave room for doubt, a skin biopsy provides more definitive answers. Pathologists look for abnormal accumulation of mast cells in the dermis, staining the tissue with markers called CD117 (the most sensitive stain) and tryptase (the most specific). The distribution pattern matters too. “Sheet-like” and “subepidermal” patterns of mast cell clustering are strongly specific for mastocytosis. A mast cell density above 66 per square millimeter helps distinguish mastocytosis from conditions that can mimic it, like chronic urticaria. A threshold where mast cells make up more than 40% of inflammatory cells in the biopsy has a specificity approaching 100%.
Confirming skin involvement does not rule out systemic disease. Adults with cutaneous findings are typically evaluated further to determine whether mast cells have infiltrated the bone marrow or other organs.
Bone Marrow Biopsy: The Central Test
A bone marrow biopsy is the cornerstone of diagnosing systemic mastocytosis. The WHO’s single major criterion is finding multifocal dense clusters of 15 or more mast cells in the bone marrow (or another organ outside the skin). Meeting this one major criterion plus one minor criterion, or meeting three minor criteria without the major one, confirms the diagnosis.
During the biopsy, pathologists examine both the tissue sample and a smear of the aspirated marrow. They look at the shape and appearance of the mast cells. In systemic mastocytosis, at least 25% of mast cells typically appear spindle-shaped or otherwise atypical rather than round. This counts as a minor criterion.
Flow Cytometry on Bone Marrow
Part of the bone marrow workup involves flow cytometry, a technique that identifies proteins on the surface of individual cells. Normal mast cells do not express certain surface markers. Neoplastic (clonal) mast cells in systemic mastocytosis abnormally display CD25, CD2, or CD30 on their surface. Finding any of these counts as a minor criterion. CD25 is the most commonly detected, and a cutoff of 60% of mast cells expressing CD25 has been shown to identify systemic mastocytosis while minimizing false positives. It’s worth noting that CD25 expression can occasionally appear on mast cells in other contexts, particularly in bone marrow samples taken after chemotherapy, so it’s interpreted alongside the other criteria rather than in isolation.
Genetic Testing for the KIT Mutation
The vast majority of systemic mastocytosis cases involve a specific genetic mutation called KIT D816V. This is a point mutation in the gene that encodes a receptor on mast cells, causing them to grow and survive uncontrollably. Detecting this mutation in bone marrow or blood counts as a minor diagnostic criterion.
The testing method makes a significant difference. Standard genetic sequencing (next-generation sequencing, or NGS) misses many cases because the mutated cells can be a tiny fraction of the total sample. A newer technique called droplet digital PCR can detect the mutation at concentrations as low as 0.03% of cells, compared to the much higher threshold NGS requires. In a comparison of both methods on the same samples, the high-sensitivity test identified 37.6% of samples as positive while standard sequencing found only 6.0%. That means standard sequencing had just 16% sensitivity compared to the more precise method.
This gap is clinically important. If your genetic test comes back negative on standard sequencing, it does not definitively rule out the mutation. Bone marrow samples are more likely to test positive (about 35% positivity) than peripheral blood draws (about 11%), which is one reason bone marrow biopsy remains central to the diagnostic process. When systemic mastocytosis is strongly suspected but standard testing is negative, requesting the higher-sensitivity assay can be the difference between a diagnosis and a miss.
Putting the Criteria Together
The WHO diagnostic framework works like a checklist. You need either the major criterion plus one minor, or three minor criteria:
- Major criterion: Dense clusters of 15 or more mast cells in bone marrow or another organ outside the skin
- Minor criterion 1: At least 25% of mast cells are spindle-shaped or atypical
- Minor criterion 2: KIT mutation detected at codon 816 or another critical region
- Minor criterion 3: Mast cells express CD2, CD25, or CD30
- Minor criterion 4: Baseline serum tryptase above 20 ng/mL
There’s one important exception to the tryptase criterion. If you have an unrelated blood cancer, an elevated tryptase doesn’t count toward the mastocytosis diagnosis. Similarly, some people carry a hereditary condition called alpha-tryptasemia that naturally raises tryptase levels, and the threshold needs to be adjusted in those cases.
Classifying Severity With B-Findings and C-Findings
Once systemic mastocytosis is confirmed, the next step is determining how aggressive it is. This is where “B-findings” and “C-findings” come in. B-findings indicate a high burden of disease without organ failure. C-findings indicate actual organ damage caused by mast cell infiltration.
B-findings include a serum tryptase above 200 ng/mL, bone marrow that appears overcrowded with signs of abnormal blood cell production, and enlargement of the liver, spleen, or lymph nodes without functional impairment. When two or three B-findings are present, the diagnosis is smoldering systemic mastocytosis, a form that carries a higher risk of progression than indolent disease but has not yet caused organ damage.
C-findings represent organ failure driven by mast cell infiltration. These include severe drops in blood cell counts (such as hemoglobin below 10 g/dL or platelets below 100,000), liver enlargement with ascites or portal hypertension, spleen enlargement with hypersplenism, malabsorption with weight loss and low albumin, or large bone lesions with pathologic fractures and severe osteoporosis. A single C-finding is enough to classify the disease as aggressive systemic mastocytosis, which requires a fundamentally different treatment approach than indolent forms.
Distinguishing Mastocytosis From Mast Cell Activation Syndrome
Many people searching for a mastocytosis diagnosis are also trying to sort out whether their symptoms point to mast cell activation syndrome (MCAS) instead. The two conditions overlap in symptoms but differ in a critical way: mastocytosis involves an abnormal accumulation of mast cells (usually driven by the KIT mutation), while MCAS involves normal or near-normal numbers of mast cells that release their contents too easily.
MCAS is diagnosed when three criteria are all met: recurrent symptoms consistent with mast cell activation affecting two or more organ systems, a documented rise in tryptase during an episode compared to baseline, and improvement with medications that block mast cell activity. If clonal markers are present, specifically the KIT D816V mutation or CD25/CD2 expression on mast cells, but the full criteria for systemic mastocytosis aren’t met, the diagnosis falls into a middle category called monoclonal mast cell activation syndrome. This is essentially a pre-mastocytosis state where clonal mast cells exist but haven’t accumulated enough to meet the WHO threshold.
The practical takeaway is that a negative bone marrow biopsy doesn’t necessarily mean your symptoms aren’t mast cell-related. It may simply redirect the diagnosis from mastocytosis to one of the mast cell activation disorders, which are managed differently.